OBJECTIVE: Invasive fetal testing is indicated for pregnancies at elevated risk of genetic abnormalities; however, the optimal testing strategy is unknown. SMFM recommends chromosomal microarray (CMA) in cases where fetal anomalies are identified. Otherwise, the choice between CMA and karyotype is unclear. The option of a rapidly resulting test such as FISH is omitted from guidelines. We hypothesize that a FISH-based reflex testing strategy with FISH followed by karyotype for abnormal FISH results and CMA for normal FISH results will yield shorter time to results and lower cost to the patient and health system. STUDY DESIGN: We conducted a retrospective cohort analysis from a single health system over 2 years to compare the result wait time and determine cost per patient for different testing strategies. Two strategies were used during this interval: a guideline-based strategy with the option of FISH based on clinical scenario and a FISHbased reflex strategy. Actionable results were defined as either an abnormal FISH result or CMA/karyotype result if normal FISH. Diagnostic results were defined as the final diagnostic test result. Descriptive statistics were used to compare demographic characteristics between the two strategies. Outcomes were compared using the t-test. Cost analysis was performed using 2018 costs as billed to insurers. RESULTS: Eighty-six patients were included in this study with 36 in the reflex strategy and 50 in the guideline strategy. Demographic characteristics between testing strategies were similar, including maternal age and indication for testing. Actionable results were reported sooner for the reflex-based strategy (9.5 AE 8.5 vs 10.5 AE 4.9 days, p ¼ 0.48). Diagnostic results were reported sooner for the guideline-based strategy (10.7 AE 4.9 vs 12.4 AE 6.7 days, p ¼ 0.21). Additionally, the costs per patient were significantly less for the guideline-based strategy ($1637 vs $2134, p ¼ 0.02). CONCLUSION: A prenatal diagnostic testing strategy based on SMFM guidelines is associated with lower costs. The time to actionable and diagnostic results was similar between a guideline-based and reflexbased strategy; however, the shorter actionable result time noted in a reflex-based strategy may be clinically significant if testing is performed in time-sensitive scenarios. These results advocate for inclusion of recommendations regarding FISH testing in future SMFM guidelines. OBJECTIVE: To discuss the findings of Integrated Genetics' informaSeq NIPS results with regard to confirmed maternal malignancies and benign tumors. STUDY DESIGN: Samples were received for NIPS and analyzed by means of massively parallel sequencing. Abnormal results were recorded in a database maintained by the genetic counselors, and follow-up information was collected 6 weeks post-results and postdelivery if needed. RESULTS: Since its launch in August 2014, 401,900 samples have been received for informaSeq NIPS. Of all of these samples, 11 cases had a confirmed maternal malignancy or benign tumor: four related to lymphoma, two breast cancer, one a thyroid mass, one maternal fibroids, one stage 4 tracheal carcinoma, one pituitary macroadenoma, and one a confirmed unspecified maternal cancer. Six of the cases resulted as multiple aneuploidies being detected, five of which also discussed an atypical pattern (special wording), four additional cases reported as a single aneuploidy but with an atypical pattern, and one case was reported as simply a single aneuploidy. Of note, trisomy 13 was indicated in 7/11 (63.6%) of the cases. CONCLUSION: This research adds to the evidence that maternal neoplasms can affect the results of non-invasive prenatal screening. These examples also show the variety of NIPS results that have been reported for patients experiencing maternal malignancy. Patients should be counseled appropriately that such results are possible. Future research may aim to develop guidelines for providers on how to follow-up when such results are received. 

